Celastrol protects ischaemic myocardium through a heat shock response with up-regulation of haeme oxygenase-1

British Journal of Pharmacology

Volumn 171, Issue 23, 2014, Pages 5265-5279

  Der Sarkissian, S ^a,b   Cailhier, J F ^a,b,c   Borie, M ^a   Stevens, L M ^a,b   Gaboury, L ^b,d   Mansour, S ^a,b   Hamet, P ^a,b   Noiseux, N ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d Institut du Cancer de Montreal   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CELASTROL; CHAPERONIN 60; CREATINE; GAMMA GLUTAMYLTRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEME OXYGENASE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TROPONIN T; URIC ACID; VASCULOTROPIN; CARDIOTONIC AGENT; DNA BINDING PROTEIN; HEAT SHOCK TRANSCRIPTION FACTOR; HEME OXYGENASE; HMOX1 PROTEIN, RAT; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRIPTERINE; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPOXIA; CELL INFILTRATION; CELL SURVIVAL; CELL VIABILITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART CONTRACTION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HEAT SHOCK RESPONSE; HISTOPATHOLOGY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANOXIA; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; HEART MUSCLE; METABOLISM; MYOCARDIAL ISCHEMIA; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANOXIA; CARDIOTONIC AGENTS; CELL LINE; CELL SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HEAT-SHOCK RESPONSE; HEME OXYGENASE (DECYCLIZING); HSP70 HEAT-SHOCK PROTEINS; MAP KINASE SIGNALING SYSTEM; MYOCARDIAL ISCHEMIA; MYOCARDIUM; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTORS; TRITERPENES; UP-REGULATION;

EID: 84925967544     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12838     Document Type: Article

References (53)

1. Aceros H, Farah G, Cobos-Puc L, Stabile AM, Noiseux N, Mukaddam-Daher S, (2011). Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt. Br J Pharmacol 164: 946-957.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. British Journal of Pharmacology, 170: 1797-1867.
3. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C, (2001). Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 25: 1341-1357.
4. Blagg BS, Kerr TD, (2006). Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 26: 310-338.
5. Chadli A, Felts SJ, Wang Q, Sullivan WP, Botuyan MV, Fauq A, et al. (2010). Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23. J Biol Chem 285: 4224-4231.
6. Chen G, Zhang X, Zhao M, Wang Y, Cheng X, Wang D, et al. (2011). Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer 11: 170.
7. Chow AM, Tang DW, Hanif A, Brown IR, (2012). Induction of heat shock proteins in cerebral cortical cultures by celastrol. Cell Stress Chaperones 18: 155-160.
8. Chu C, He W, Kuang Y, Ren K, Gou X, (2014). Celastrol protects kidney against ischemia-reperfusion-induced injury in rats. J Surg Res 186: 398-407.
9. Daiber A, (2010). Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 1797: 897-906.
10. Dawn B, Bolli R, (2005). HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection? Am J Physiol Heart Circ Physiol 289: H522-H524.
11. Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, et al. (2008). Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51: 712-718.
12. Finegold JA, Asaria P, Francis DP, (2013). Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol 168: 934-945.
13. Grotendorst GR, Rahmanie H, Duncan MR, (2004). Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 18: 469-479.
14. Haider H, Ashraf M, (2008). Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 45: 554-566.
15. Hamilton JA, Lacey DC, Turner A, de Kok B, Huynh J, Scholz GM, (2012). Hypoxia enhances the proliferative response of macrophages to CSF-1 and their pro-survival response to TNF. PLoS ONE 7: e45853.
16. Hansen J, Palmfeldt J, Vang S, Corydon TJ, Gregersen N, Bross P, (2011). Quantitative proteomics reveals cellular targets of celastrol. PLoS ONE 6.
17. Hillion JA, Li Y, Maric D, Takanohashi A, Klimanis D, Barker JL, et al. (2006). Involvement of Akt in preconditioning-induced tolerance to ischemia in PC12 cells. J Cereb Blood Flow Metab 26: 1323-1331.
18. Jackson SE, (2013). Hsp90: structure and function. Top Curr Chem 328: 155-240.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Laflamme MA, Zbinden S, Epstein SE, Murry CE, (2007). Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Ann Rev Pathol 2: 307-339.
21. Li Y, He D, Zhang X, Liu Z, Zhang X, Dong L, et al. (2012). Protective effect of celastrol in rat cerebral ischemia model: down-regulating p-JNK, p-c-Jun and NF-kappaB. Brain Res 1464: 8-13.
22. Liu SX, Zhang Y, Wang YF, Li XC, Xiang MX, Bian C, et al. (2012). Upregulation of heme oxygenase-1 expression by hydroxysafflor yellow A conferring protection from anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int J Cardiol 160: 95-101.
23. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
24. Murry CE, Jennings RB, Reimer KA, (1991). New insights into potential mechanisms of ischemic preconditioning. Circulation 84: 442-445.
25. Nguyen BK, Maltais S, Perrault LP, Tanguay JF, Tardif JC, Stevens LM, et al. (2010). Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res 3: 547-558.
26. Noiseux N, Borie M, Desnoyers A, Menaouar A, Stevens LM, Mansour S, et al. (2012). Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology 153: 5361-5372.
27. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A, et al. (2006). Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 14: 840-850.
28. Ovize M, Thibault H, Przyklenk K, (2013). Myocardial conditioning: opportunities for clinical translation. Circ Res 113: 439-450.
29. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, et al. (2010). Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7: 17.
30. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
31. Pfaffl MW, (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
32. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD, (2004). Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 322: 778-786.
33. Salminen A, Lehtonen M, Paimela T, Kaarniranta K, (2010). Celastrol: molecular targets of thunder god vine. Biochem Biophys Res Commun 394: 439-442.
34. Santiago JJ, Dangerfield AL, Rattan SG, Bathe KL, Cunnington RH, Raizman JE, et al. (2010). Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 239: 1573-1584.
35. Sarkar S, Dutta D, Samanta SK, Bhattacharya K, Pal BC, Li J, et al. (2013). Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo. Int J cancer 132: 695-706.
36. Schett G, Steiner CW, Groger M, Winkler S, Graninger W, Smolen J, et al. (1999). Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. FASEB J 13: 833-842.
37. Seo WY, Goh AR, Ju SM, Song HY, Kwon DJ, Jun JG, et al. (2011). Celastrol induces expression of heme oxygenase-1 through ROS/Nrf2/ARE signaling in the HaCaT cells. Biochem Biophys Res Commun 407: 535-540.
38. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al. (2005). Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112: 3738-3744.
39. Sorescu D, Griendling KK, (2002). Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fai 8: 132-140.
40. Sreeramulu S, Gande SL, Gobel M, Schwalbe H, (2009). Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 48: 5853-5855.
41. Stabile AM, Aceros H, Stockmeyer K, Abdel Rahman AA, Noiseux N, Mukaddam-Daher S, (2011). Functional and molecular effects of imidazoline receptor activation in heart failure. Life Sci 88: 493-503.
42. Sun J, Sun G, Meng X, Wang H, Wang M, Qin M, et al. (2013). Ginsenoside RK3 prevents hypoxia-reoxygenation induced apoptosis in H9c2 cardiomyocytes via AKT and MAPK pathway. Evid Based Complement Alternat Med 2013: 690190.
43. Sun Y, (2009). Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 81: 482-490.
44. Taipale M, Jarosz DF, Lindquist S, (2010). HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515-528.
45. Wang W, Liu K, Dong H, Liu W, (2008). High-performance liquid chromatography spectrometric analysis of tripterin in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 863: 163-166.
46. Watkins SJ, Borthwick GM, Arthur HM, (2011). The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 47: 125-131.
47. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, et al. (2004). Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279: 56053-56060.
48. Yoon YJ, Kim JA, Shin KD, Shin DS, Han YM, Lee YJ, et al. (2011). KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J Biol Chem 286: 1737-1747.
49. Yu X, Tao W, Jiang F, Li C, Lin J, Liu C, (2010). Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am J Hypertens 23: 895-903.
50. Zhang J, Li CY, Xu MJ, Wu T, Chu JH, Liu SJ, et al. (2012). Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. J Ethnopharmacol 144: 195-200.
51. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al. (2008). A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7: 162-170.
52. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D, (2009). Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 284: 35381-35389.
53. Zordoky BN, El-Kadi AO, (2007). H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56: 317-322.